What is known and objective: An effective rapid-onset treatment for major depressive disorder could save lives. Extensive preclinical and clinical data demonstrate such an action of ketamine. However, the presumptive mechanism of action, inhibition of NMDA (N-methyl-D-aspartate) receptors, has recently been challenged. Elucidation of the mechanism is important clinically for drug discovery and for understanding the (patho)physiology of depression.
| WHAT IS KNOWN AND OBJECTIVE
Current therapy for treatment of depressive disorders, whether pharmacologic or non-pharmacologic, often requires weeks of treatment before clinically significant improvement is noted. 1 The lag time between initiation of therapy and the onset of clinical effectiveness is serious, because depressed patients are at increased risk of suicide, 2 and perhaps at increased risk during the lag time. 3, 4 In addition, the delay raises questions about the apparent disconnect between the clinical effect and the molecular mechanism of antidepressant drugs. For example, inhibition of the neuronal reuptake of serotonin or noradrenaline occurs quickly; 5 thus, there is disconnect between the molecular events, which occur rapidly, and the clinical effect, which is delayed.
The extensive preclinical and clinical evidence that convincingly demonstrates a rapid-onset antidepressant action of ketamine was previously reviewed. 6 The findings are both exciting and surprising.
They are exciting because the reduction in delay between therapy initiation and clinical benefit is potentially life-saving; and they are surprising because no other therapeutic intervention works so rapidly, and because ketamine is most widely known as being an analgesic agent, 7 not as an antidepressant. Unfortunately, there are undesirable aspects of ketamine that will likely limit its widespread use for this purpose, namely dysphoric effects and abuse potential. 8 In order that more clinically amenable compounds can be discovered or developed, it is important to understand the mechanism(s) by which ketamine produces its rapid antidepressant effect.
| COMMENTARY
A recent report by Zanos et al published in Nature 9 proposes that (i) a metabolite of ketamine, actually one enantiomer of the metabolite, is necessary and sufficient to produce the antidepressant effect of ketamine and (ii) it does so not by inhibition of the NMDA (N-methyl-Daspartate) subtype of glutamate receptor, but instead by activation of the AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid)
subtype. The evidence proposed to question the "NMDA hypothesis" includes the following:
• (S)-ketamine is a more potent inhibitor of the NMDA receptor than (R)-ketamine, 10,11 but (R)-ketamine is the more potent antidepressant (which is not due to higher brain levels) 12 and
• different NMDA receptor antagonists, including MK801, do not produce the same antidepressant effect as does ketamine. 9, 13, 14 The evidence in favour of the alternative "NMDA-independent" hypothesis includes the findings that:
• inhibition of the metabolism of ketamine, but not its binding affinity or levels in the brain, eliminates its antidepressant action,
9
• in humans, the antidepressant effect of ketamine correlates with the plasma levels of its metabolite (2S,6S;2R,6R)-hydroxynorketamine (HNK),
15
• the metabolite of (R)-ketamine (2R,6R)-HNK produces a dose-dependent antidepressant effect, which is not a result of higher brain levels, compared to (2S,6S)-ketamine, which is a metabolite of (S)- Together, the data suggest that (2R,6R)-HNK induces an initial increase in glutamate signalling, followed by a longer-lasting compensatory upregulation of synaptic AMPA receptors.
A countervailing view to the NMDA receptor-independent hypothesis is held by Suzuki et al. 16 They present the following evidence, among others, for an NMDA receptor-dependent mechanism of ketamine's antidepressant effects:
• (2R,6R)-HNK blocks synaptic NMDA receptors in a similar manner as ketamine,
• (2R,6R)-HNK elicits the same signal transduction pathway as does ketamine,
• the effects of (2R,6R)-HNK on intracellular signalling are coupled to 
-HNK (2R,5S)-HNK (2R,4S)-HNK (2R,4R)-HNK (2R,6S)-HNK (2R,6S)-HK (2S,6R)-HNK (2S,6R)-HK (2S,6S)-HK (2S,6S)-HNK (2S,5S)-HNK (2S,5R)-HNK (2S,4R)-HNK (2S,4S)-HNK (2R,6R)-HK (2R,6R)-HNK
attenuates the activity of the enzyme eEF2 kinase (eukaryotic elongation factor 2 kinase; also known as calmodulin-dependent protein kinase III) 
16
Can the opposing points of view be harmonized? Suzuki et al 16 suggest that the time course of effects might give a clue to the answer. While ketamine has a relatively short half-life, its antidepressant effects are relatively long-lasting, in fact exceeding the time that the drug is detectable in the blood. They propose that the initial effect is due to ketamine's direct action at NMDA receptors, and the extended effect is due to (2R,6R)-HNK, by indirect inhibition of NMDA receptors.
Nevertheless, the exact mechanism by which ketamine produces its rapid-onset antidepressant effect remains unknown. The best-characterized molecular action of ketamine is use-dependent non-competitive antagonism of the NMDA subtype of glutamate receptor, 17 and this is the default presumptive mechanism for its antidepressant effect. Ketamine has been shown to improve measures of depressive symptoms, such as depressed mood and anhedonia, and reduce suicidal thoughts in treatment-refractory patients (unipolar and bipolar) at doses lower than used for anaesthesia. [18] [19] [20] [21] [22] The onset of effects can be as short as a few hours or days after a single administration, and the effect persists for days or a week, long enough for other antidepressant therapy to begin to become effective. 6 Unfortunately, ketamine suffers from adverse effects and abuse potential. 23 Thus, there is impetus for the discovery of other substances with the same on-target (antidepressant) effect, but with less off-target effects.
But what, exactly, is the target for ketamine-induced antidepressant effect?
A body of evidence strongly implicates inhibition of the NMDA receptor as the mechanism of ketamine's antidepressant action. Although there is strong evidence for the prevailing theories that implicate NMDA or AMPA receptors, ketamine binds promiscuously to other receptor types, and therefore, it has rather complex pharmacology. One or more of these other mechanisms might be responsible, or contributory, to the antidepressant effect. 24 Inhibition of NMDA receptors is the best-known molecular action of ketamine, but ketamine has additional pharmacologic actions at other sites, including 25 nicotinic acetylcholine ion channels, delta-and mu-opioid receptors, the nitric oxide (NO)-cyclic guanosine monophosphate (cGMP) system, aminergic neuromodulators (dopamine and noradrenaline), neurosteroids and L-type Ca 2+ channels.
| WHAT IS NEW AND CONCLUSION
Ketamine's surprising, but well-documented, rapid-onset antidepressant action has reinvigorated the hope, and search, for better pharmacotherapeutic treatments for depressive disorders. Ketamine, its own use limited because of its adverse effects, provides a new impetus for uncovering the still unknown (patho)physiology of depression (which, due to ketamine's unexpected efficacy, might be a heretofore
The NMDA receptor is composed of two NR1 subunits and two (or more) NR2 subunits. 
